Preview: Zamalek eyeing revenge over depleted Ahly in Cairo derby    Messi nets 2, Barcelona beat Bilbao 4-0 to win Copa del Rey    Libya welcomes UN decision to deploy cease-fire monitors    Morocco's Ziyech fires Chelsea to win over Man City in FA Cup semi-final    France reports daily decline in COVID-19 patients in intensive care    Egypt to launch artistic Ramadan Nights Festival    MCDR to start board nomination procedures on Sunday    Sudan wants legally binding agreement on Ethiopia's Nile Dam, not war: Al-Burhan    Egyptian architects win UNESCO competition to rebuild Mosul's Al-Nouri Mosque    Tunisia closes schools until April 30 to slow spread of coronavirus    Egypt's Environment Minister witnesses closing of training on sanitary landfills    Egypt demands fair distribution of COVID-19 vaccines    Egypt launches technical competence programme for Higher Education Ministry staff    'El-Malek' series resumes filming following outcry    Egypt's Cultural Development Fund begins Ramadan programme    Five people killed as police fire at protesting workers in Bangladesh    Egypt joins JPMorgan Chase government bond index watch list    Egypt, Pakistan may sign an MoU between Suez Canal Authority, Gwadar Port Authority    Funeral to praise Philip's 'courage' and support for queen    Egypt urges dissuading Ethiopia from taking unilateral action on GERD in letter to UNSC    Biden says Iranian enrichment to 60% unhelpful, but glad about talks    Sisi stresses to Djibouti president importance of reaching GERD settlement to avoid regional instability    We will resort to international community after all GERD negotiations finish: Egypt FM    President Sisi supports Eni expanding operations in Egypt    10 emerging writers receive $50,000 Whiting Awards    J.K. Rowling children's story 'The Christmas Pig' out in October    2 crew members of impounded Ever Given allowed to return home for personal emergencies: Suez Canal Authority    Egypt condemns continued attacks by Yemen's Houthi militias towards Saudi territory    Turkey to send delegation to Egypt in May, its foreign minister says    EFG Hermes determines fair value of Arab Investment Bank at EGP1.1bln    SODIC hires Hermes to study acquisition offer by Aldar Properties    Veteran Egyptian journalist Makram Mohamed Ahmed passes away at 86    Fans allowed at opening match of UEFA EURO 2020: Italy    Egypt halts traditional amateur football tournaments during Ramadan    Al Ahly get ready for fierce league clash against Zamalek    Egypt Press Syndicate condemns Health Ministry's alleged media obstruction    Egypt tourism minister discusses preparations for upcoming Arabian Travel Market with UAE    Egypt, Turkey eye new phase of bilateral relations    Egyptian farmers fearful as Ethiopia goes for 2nd Blue Nile dam filling    Party consensus    Russian FM says Egypt is main partner in Middle East, Africa    Egypt sees an uptick in new coronavirus infections registers 801 new cases on Saturday    PMI moves towards a smoke-free transformation, takes part in a webinar on e-cigarettes    Allianz Egypt partners with IGNITE to equip brand ambassadors for 2021 Olympics    Hassan Allam consortium wins contract to manage, operate Grand Egyptian Museum    Enhanced Labs signs Mr. Olympia 2020 "Big Ramy" And His Trainer Dennis James    King Tutankhamun funerary mask is must-see tourist icon: The Telegraph    Seasoned Egyptian screenwriter Wahid Hamed dies at 76    







Thank you for reporting!
This image will be automatically disabled when it gets reported by several people.





China's CAS COVID-19 vaccine induces immune response in mid-stage tests
Published in Ahram Online on 23 - 12 - 2020

A coronavirus vaccine candidate developed by the Chinese Academy of Sciences (CAS) was found to be safe and triggered immune responses in early and mid-stage trials, researchers said on Tuesday.
A late-stage trial of the ZF2001 vaccine, which CAS is developing with a unit of Chongqing Zhifei Biological Products , began last month in China. It aims to recruit 29,000 people across China, Uzbekistan, Indonesia, Pakistan and Ecuador.
The candidate did not cause serious adverse events, with common mild side-effects including injection pain, redness and swelling, researchers at the Chongqing Zhifei unit, CAS, and other Chinese institutes said in a paper published on Tuesday ahead of peer review.
The combined data from Phase 1 and 2 trials involved 950 healthy Chinese participants aged 18-59. Low dose and high dose versions were tested, and the Phase 2 study also tested two doses versus three doses for both the low dose and high dose versions.
The higher dose given via three injections spaced 30 days apart did not induce an improved immune reponse compared to the lower dose, the paper said. The Phase 3 trial will look at the lower dose version given over three injections, it said.
Neutralising antibodies against the virus were detected among at least 93% participants who received three shots in different groups. The levels of vaccine-triggered antibodies were higher than those seen in samples of patients recovered from the disease, researchers said.
However, these antibody-based readings are on their own not sufficient to predict how effective ZF2001 will be in protecting people from the virus, researchers said, warning they could not yet determine the duration of immune responses.
The vaccine also triggered moderate cell-based immune responses, a crucial part of the human immune system that works differently from antibodies.
ZF2001 is a protein subunit vaccine, which uses a harmless piece of the SARS-CoV-2 virus rather than the entire germ.
Four other Chinese vaccines from Sinopharm, Sinovac Biotech and CanSino Biologics have also entered Phase 3 clinical trials.


Clic here to read the story from its source.